Cryoport, Inc. (NASDAQ:CYRX) Shares Sold by Greenwood Capital Associates LLC

Greenwood Capital Associates LLC lessened its stake in Cryoport, Inc. (NASDAQ:CYRX) by 15.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 67,234 shares of the company’s stock after selling 12,099 shares during the quarter. Greenwood Capital Associates LLC’s holdings in Cryoport were worth $523,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Thematics Asset Management increased its holdings in Cryoport by 176.2% in the third quarter. Thematics Asset Management now owns 1,705,000 shares of the company’s stock valued at $13,828,000 after buying an additional 1,087,800 shares during the last quarter. Fred Alger Management LLC grew its position in shares of Cryoport by 49.9% in the 3rd quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company’s stock worth $21,887,000 after acquiring an additional 898,481 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Cryoport in the 3rd quarter valued at approximately $3,405,000. JPMorgan Chase & Co. increased its holdings in shares of Cryoport by 1,464.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 305,237 shares of the company’s stock valued at $2,475,000 after acquiring an additional 285,726 shares during the last quarter. Finally, Algert Global LLC raised its position in shares of Cryoport by 282.7% during the 3rd quarter. Algert Global LLC now owns 247,483 shares of the company’s stock valued at $2,007,000 after acquiring an additional 182,808 shares in the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

Insiders Place Their Bets

In related news, Director Ramkumar Mandalam sold 7,369 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $7.46, for a total transaction of $54,972.74. Following the transaction, the director now owns 59,497 shares in the company, valued at $443,847.62. This trade represents a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jerrell Shelton sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $6.78, for a total value of $339,000.00. Following the sale, the chief executive officer now directly owns 712,747 shares in the company, valued at approximately $4,832,424.66. The trade was a 6.56 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 109,869 shares of company stock worth $735,673. 10.10% of the stock is owned by company insiders.

Cryoport Trading Down 5.3 %

Shares of NASDAQ:CYRX opened at $6.99 on Wednesday. Cryoport, Inc. has a fifty-two week low of $5.32 and a fifty-two week high of $20.10. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. The company has a market cap of $345.52 million, a PE ratio of -2.07 and a beta of 1.59. The company’s 50-day moving average price is $7.86 and its 200 day moving average price is $7.93.

Cryoport (NASDAQ:CYRX) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.23. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The business had revenue of $56.66 million during the quarter, compared to the consensus estimate of $58.13 million. During the same period in the previous year, the firm posted ($0.31) earnings per share. Sell-side analysts anticipate that Cryoport, Inc. will post -0.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Guggenheim assumed coverage on shares of Cryoport in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective for the company. UBS Group lifted their price target on shares of Cryoport from $7.00 to $9.00 and gave the company a “neutral” rating in a report on Friday, October 18th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Cryoport in a research report on Friday, January 17th. Finally, Roth Mkm cut their target price on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $12.29.

Cryoport Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.